These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17175924)

  • 1. [Use of antimuscarinics in patients with lower urinary tract symptoms for BPH and overactive bladder].
    Ruiz Cerdá JL
    Actas Urol Esp; 2006 Oct; 30(9):849-55. PubMed ID: 17175924
    [No Abstract]   [Full Text] [Related]  

  • 2. [Use of antimuscarinics in patients with LUTS-BPH and OAB symptoms: clinical expertise and resistance to lose the fear to urinary retention risk].
    Ruiz Cerdá JL
    Actas Urol Esp; 2008; 32(10):957-60. PubMed ID: 19143285
    [No Abstract]   [Full Text] [Related]  

  • 3. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of muscarinic receptor antagonists in the treatment of men with lower urinary tract symptoms secondary to BPH].
    Kaplan SA
    Actas Urol Esp; 2007 Feb; 31(2):86-91. PubMed ID: 17645086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia.
    Kaplan SA
    J Urol; 2011 Apr; 185(4):1386. PubMed ID: 22098979
    [No Abstract]   [Full Text] [Related]  

  • 6. Defining the role of overactive bladder treatments in men with lower urinary tract symptoms.
    Lemack GE
    Nat Clin Pract Urol; 2007 Apr; 4(4):174-5. PubMed ID: 17415351
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of use of urinary antimuscarinics and alpha blockers for benign prostatic hyperplasia in older adults at risk of falls: a clinical review.
    İlhan B; Erdoğan T; Topinková E; Bahat G;
    Eur Geriatr Med; 2023 Aug; 14(4):733-746. PubMed ID: 37245173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of men with lower urinary tract symptoms and overactive bladder.
    Chai TC
    JAMA; 2007 Mar; 297(11):1191-2; author reply 1193. PubMed ID: 17374808
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Speakman MJ
    Eur Urol; 2009 Sep; 56(3):542-3. PubMed ID: 19070420
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Dmochowski R
    Eur Urol; 2009 Sep; 56(3):542. PubMed ID: 19070419
    [No Abstract]   [Full Text] [Related]  

  • 11. Lower urinary tract symptoms (LUTS) in men: thinking beyond the prostate.
    Elsamra S; Ellsworth PS
    Med Health R I; 2010 Feb; 93(2):53-6. PubMed ID: 20329627
    [No Abstract]   [Full Text] [Related]  

  • 12. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study.
    Yamaguchi O; Kakizaki H; Homma Y; Takeda M; Nishizawa O; Gotoh M; Yokoyama O; Seki N; Yoshida M;
    Urology; 2011 Jul; 78(1):126-33. PubMed ID: 21601248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of men with lower urinary tract symptoms and overactive bladder.
    Bell WA; Amarshi N
    JAMA; 2007 Mar; 297(11):1192; author reply 1193. PubMed ID: 17374810
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical management of lower urinary tract symptoms with combined medical therapy.
    Roehrborn CG
    BJU Int; 2008 Nov; 102 Suppl 2():13-7. PubMed ID: 19032605
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of men with lower urinary tract symptoms and overactive bladder.
    Young JG; Subramonian K
    JAMA; 2007 Mar; 297(11):1192-3; author reply 1193. PubMed ID: 17374809
    [No Abstract]   [Full Text] [Related]  

  • 16. Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia.
    Chapple C
    Curr Opin Urol; 2010 Jan; 20(1):43-8. PubMed ID: 19875964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Analysis of the Effects of Executive Functions, Working Memory and Other Factors on Medication Adherence in Elderly Men with Benign Prostatic Hyperplasia and Overactive Bladder Symptoms.
    Kosilov K; Kuzina I; Kuznetsov V; Kosilova L; Ivanovskaya M; Kosilova E
    Curr Aging Sci; 2020; 13(1):72-80. PubMed ID: 31560296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams.
    Chung DE; Te AE; Staskin DR; Kaplan SA
    Urology; 2010 May; 75(5):1144-8. PubMed ID: 20206978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: Results from a randomized pilot study.
    Sakalis V; Sfiggas V; Vouros I; Salpiggidis G; Papathanasiou A; Apostolidis A
    Int J Urol; 2018 Aug; 25(8):737-745. PubMed ID: 30008188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity].
    Gan W; Zhang SF; Jia HT; Xie S; Luo MH; Li YF
    Zhonghua Nan Ke Xue; 2011 Apr; 17(4):348-50. PubMed ID: 21548214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.